Dig deeper in Learning Studios
Learn from industry leaders as they present the latest in cardiovascular practices, products, services and innovative technologies advancing treatment.
These events are not part of the official Scientific Sessions 2020 program as planned by the AHA Committee on Scientific Sessions Program. Check the “AHA Conferences” Mobile App for a complete list of updated programming.
Here are the opportunities:
Friday, Nov. 13
1:30-2:15 p.m. CST
Importance of Real-World Evidence in Understanding Current Lipid Management in Patients With ASCVD: A Focus on MI (LS.01)
Industry Speaker: Nihar R. Desai, New Haven, Connecticut
Sponsored by Amgen, Inc.
1:30-2:15 p.m. CST
Selecting a First-Choice Therapy for Systolic HF: Meeting the Burden of Proof (LS.02)
Sponsored by Novartis Pharmaceuticals Corporation
Industry Speaker: Javed Butler
1:30-2:15 p.m. CST
Transthyretin Cardiac Amyloidosis (ATTR-CM) Considerations and Clinical Challenges: Identifying, Confirming and Treating Patients (LS.03)
Industry speaker: Catherine Marti, Georgia
Sponsored by Pfizer, Inc.
2:30-3:15 p.m. CST
Exploring Worsening Heart Failure Events in Patients With Chronic Heart Failure With Reduced Ejection Fraction (LS.06)
Sponsored by Merck Sharp and Dohme Corp.
2:45-3:30 p.m. CST
The Next Horizon in the Heart Failure Treatment Paradigm for Patients With HFrEF: Results of the Landmark DAPA-HF Clinical Trial (LS.04)
Industry Speaker: Johanna Contreras, New York
Sponsored by AstraZeneca Pharmaceuticals LP
2:45-3:30 p.m. CST
The Cardiac Sarcomere in HFrEF and HCM: From Bedside to Bench (LS.05)
Industry Speakers: Adrian F. Hernandez, Durham, North Carolina; David A. Kass, Baltimore; and Sanjiv J. Shah, Chicago
Sponsored by Cytokinetics, Inc.
Saturday, Nov. 14
1:30-2:15 p.m. CST
VASCEPA® (icosapent ethyl): Elevating the Standard of Care (LS.07)
Industry Speaker: Payal Kohli, San Francisco
Sponsored by Amarin Parma, Inc.
1:30-2:15 p.m. CST
Jardiance® (empagliflozin) Tablets: The Impact of EMPA-REG OUTCOME (LS.08)
Industry Speaker: Narendra Singh, Johns Creek, Georgia
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA
1:30-2:15 p.m. CST
How to Identify and Manage the Hypertrophic Cardiomyopathy (HCM) That Is Hiding (LS.09)
Industry Speakers: Srihari S. Naidu, Hawthorne, New York; and Andrew Wang, Chapel Hill, North Carolina
Sponsored by MyoKardia, Inc.
1:30-2:15 p.m. CST
HFpEF: Heart Failure With Preserved Ejection Fraction (HFpEF): Pathophysiology vs Outcomes Are We Narrowing the Gap? (LS.10)
Industry Speaker: Daniel Bensimhon, North Carolina
Sponsored by Novartis Pharmaceuticals Corporation
2:45-3:30 p.m. CST
Getting to the Heart of Managing Heart Failure: Unmet Medical Need in HFrEF (LS.11)
Industry Speaker: John R. Teerlink, San Francisco
Sponsored by Amgen, Inc.
2:45-3:30 p.m. CST
Clinical Insights in Chronic CAD/PAD: Reducing the Risk of Major Cardiovascular Events (LS.12)
Industry Speaker: Vamsi S. Krishna
Sponsored by Janssen Pharmaceuticals, Inc.
Sunday, Nov. 15
1:30-2:15 p.m. CST
Optimizing LDL-C Management in Recent MI Patients: A Focus on Clinical Data (LS.13)
Industry Speaker: Matthew A. Cavender, Chapel Hill, North Carolina
Sponsored by Amgen, Inc.
1:30-2:15 p.m. CST
Clinical Insights in NVAF: Reducing the Risk of Stroke and Systemic Embolism (LS.14)
Industry Speaker: Dharmesh Patel, Memphis, Tennessee
Sponsored by Janssen Pharmaceuticals, Inc.
1:30-2:15 p.m. CST
Heart Failure With Preserved Ejection Fraction: Current Perspectives and Opportunities to Optimize Care Surrounding Hospitalization (LS.15)
Industry Speaker: Sanjiv J. Shah, Chicago
Sponsored by Novartis Pharmaceuticals Corporation
2:45-3:30 p.m. CST
Getting to the Heart of Managing Heart Failure: Advancements of Clinical Utility of HRQoL in HFrEF (LS.16)
Industry Speaker: John Spertus, Kansas City, Missouri
Sponsored by Amgen, Inc.
2:45-3:30 p.m. CST
Improving Early Outcomes for the Post-AMI Patient: Cholesterol Efflux and the Role of ApoA-I in Plaque Stabilization (LS.17)
Industry Speakers: Deepak L. Bhatt, Newton, Massachusetts; and Peter Libby, Boston
Sponsored by CSL Behring
Monday, Nov. 16
1:30-2:15 p.m. CST
An Approach to Managing Lipids: Oral, Nonstatin Therapies for Lowering LDL-C (LS.18)
Industry Speaker: Harold Edward Bays, Louisville, Kentucky
Sponsored by Esperion Therapeutics, Inc.
1:30-2:15 p.m. CST
Intensive Lipid Management: Special Subgroups [Lp(a)] – Different Clinical Practices to Achieve the Same Therapeutic Targets (LS.19)
Industry Speakers: Subhash Banerjee, Dallas; P. B. Duell, Portland, Oregon; Eugenia Gianos, New York; Patrick M. Moriarty, Kansas City, Kansas; and James A. Underberg, New York
Sponsored by Kaneka Pharma America LLC
1:30-2:15 p.m. CST
Atherosclerotic Cardiovascular Disease (ASCVD) High Risk Assessment, Evaluation and Management (LS.20)
Industry Speaker: Guy Mintz, New YorkSponsored by Novartis Pharmaceuticals Corporation
Tuesday, Nov. 17
1:30-2:15 p.m. CST
Role of Lipoprotein (a) in Atherosclerotic Cardiovascular Disease (LS.21)
Industry Speaker: Keith C. Ferdinand, New Orleans
Sponsored by Novartis Pharmaceuticals Corporation
2:30-3:15 p.m. CST
CCM® for Heart Failure – The Class Effect Assessing Heart Failure – How Are We Doing? Device Therapy for HF – Appropriate Patient Selection and Identification (LS.22)
Industry Speakers: William T. Abraham, Columbus, Ohio; Nirav Raval, Orlando, Florida; and Jagmeet P. Singh, Vestal, New York
Sponsored by Impulse Dynamics
